Advertisement

Biochemical markers of bone turnover

  • Simon P. Robins

Abstract

Much of the research effort in bone biology is directed towards understanding the mechanisms of bone modelling and remodelling. This includes attempts to elucidate the influences of a large number of biochemical and biophysical factors on cellular processes in bone. The development of techniques to quantify specific facets of these processes in bone provides important tools to facilitate research in this area. Markers of bone turnover also have more general applications clinically in the detection and management of disorders involving the skeleton. Indeed, the increasing interest in osteoporosis and related disorders in recent years has probably contributed some impetus to the major advances in developing new markers that have occurred recently.

Keywords

Bone Resorption Bone Turnover Biochemical Marker Metabolic Bone Disease Mineral Research 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Price, C. (1993) Multiple forms of human serum alkaline phosphatase: detection and quantitation. Annals of Clinical Biochemistry 30), 355–372.PubMedGoogle Scholar
  2. 2.
    Garnero, P. and Delmas, P. (1993) Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. Journal of Clinical Endocrinology and Metabolism 77), 1046–1053.PubMedCrossRefGoogle Scholar
  3. 3.
    Gomez, B. Ardakani, S., Ju, J. et al, (1995) Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clinical Chemistry 41), 1560–1566.PubMedGoogle Scholar
  4. 4.
    Price, P.A. and Nishimoto, S.K. (1980) Radioimmunoassay for the vitamin K-depen-dent protein of bone and its discovery in plasma. Proceedings of the National Academy of Sciences USA 77), 2234–2238.CrossRefGoogle Scholar
  5. 5.
    Deftos, L.J., Wolfert, R.L., Hill, C.S. and Burton, D.W. (1992) Two-site assays of bone gla protein (osteocalcin) demonstrate immunochemical heterogeneity of the intact molecule. Clinical Chemistry 38), 2318–2321.PubMedGoogle Scholar
  6. 6.
    Hellman, J., Kakonen, S., Matikainen, M. et al. (1996) Epitope mapping of nine monoclonal antibodies against osteocalcin: Combinations into two-site assays affect both assay specificity and sample stability. Journal of Bone and Mineral Research 11), 1165–1175.PubMedGoogle Scholar
  7. 7.
    Delmas, P., Christiansen, C., Mann, K. and Price, P. (1990) Bone Gla protein (osteocalcin); assay standardization report. Journal of Bone and Mineral Research 5), 5–11.PubMedGoogle Scholar
  8. 8.
    Knapen, M., Hamulyak, K. and Vermeer, C. (1989) The effect of vitamin K supplementation on circulating osteocalcin (bone gla protein) and urinary calcium excretion. Annals of Internal Medicine 111, 1001–1005.PubMedGoogle Scholar
  9. 9.
    Merle, B. and Delmas, P.D. (1990) Normal carboxylation of circulating osteocalcin (bone gla protein) in Paget’s disease of bone. Bone and Mineral 11), 237–245.PubMedCrossRefGoogle Scholar
  10. 10.
    Szulc, P., Chapuy, M., Meunier, P. and Delmas, P. (1996) Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture: a three year follow-up study. Bone 18), 487–488.PubMedCrossRefGoogle Scholar
  11. 11.
    Tracy, R., Andrianorivo, A., Riggs, B.L. and Mann, K. (1990) Comparison of monoclonal and polyclonal antibody-based immunoassays for osteocalcin: a study of sources of variation in assay results. Journal of Bone and Mineral Research 5), 451–461.PubMedGoogle Scholar
  12. 12.
    Garnero, P., Grimaux, M., Seguin, P. and Delmas, P. (1994) Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. Journal of Bone and Mineral Research 9), 255–264.PubMedGoogle Scholar
  13. 13.
    Blumsohn, A., Hannon, R. and Eastell, R. (1995) Apparent instability of osteocalcin in serum as measured with different commercially available immunoassays. Clinical Chemistry 41), 318–319.PubMedGoogle Scholar
  14. 14.
    Ducy, P., Desbois, C, Boyce, B. et al. (1996) Increased bone formation in osteocalcin-deficient mice. Nature 382), 448–452.PubMedCrossRefGoogle Scholar
  15. 15.
    Melkko, J., Niemi, S., Risteli, L. and Risteli, J. (1990) Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clinical Chemistry 36), 1328–1332.PubMedGoogle Scholar
  16. 16.
    Trivedi, P., Risteli, J., Risteli, L. et al. (1991) Serum concentrations of the type I and III procollagen propeptides as biochemical markers of growth velocity in healthy infants and children and in children with growth disorders. Pediatric Research 30), 276–280.PubMedCrossRefGoogle Scholar
  17. 17.
    Teisner, B. Rasmussen, H., ojrup, P. et al. (1992) Fetal antigen 2: an amniotic protein identified as the aminopropeptide of the alphal chain of human procollagen type I. Acta Pathologica, Microbiologica et Immunologica Scandinavica 100), 1106–1114.Google Scholar
  18. 18.
    Orum, O., Hansen, M., Jensen, C. et al. (1996) Procollagen type I N-terminal propep-tide (PINP) as an indicator of type I collagen metabolism: ELISA development, reference interval, and hypovitaminosis D induced hyperparathyroidism. Bone 19), 157–163.PubMedCrossRefGoogle Scholar
  19. 19.
    Melkko, J., Kauppila, S., Niemi, S. et al. (1996) Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clinical Chemistry 42), 947–954.PubMedGoogle Scholar
  20. 20.
    Risteli, J., Niemi, S., Kauppila, S. et al. (1995) Collagen propeptides as indicators of collagen assembly. Acta Orthopaedica Scandinavica Suppl. 266), 183–188.Google Scholar
  21. 21.
    Jensen, C., Hansen, M., Brandt, J. et al (1997) Quantification of the N-terminal propeptide of human procollagen type I (PINP): comparison of ELISA and RIA with respect to different molecular forms. Clinical Chemistry (in press).Google Scholar
  22. 22.
    Cheung, C., Panesar, N., Haines, C. et al. (1995) Immunoassay of a tartrate-resistant acid phosphatase in serum. Clinical Chemistry 41), 679–686.PubMedGoogle Scholar
  23. 23.
    Krane, S., Kantrowitz, F., Byrne, M. et al. (1977) Urinary excretion of hydroxylysine and its glycosides as an index of collagen degradation. Journal of Clinical Investigation 59), 819–827.PubMedGoogle Scholar
  24. 24.
    Moro, L., Noris-Suarez, K., Michalsky, M. et al. (1993) The glycosides of hydroxylysine are final products of collagen degradation in humans. Biochimica Biophysica Acta 1156), 288–290.Google Scholar
  25. 25.
    Segrest, J.P. and Cunningham, L.W. (1970) Variations in human urinary O-hydrox-ylysyl glycoside levels and their relationship to collagen metabolism. Journal of Clinical Investigation 49), 1497–1509.PubMedGoogle Scholar
  26. 26.
    Bienkowski, R. (1984) Intracellular degradation of newly synthesized collagen. Collagen and Related Research 4), 399–412.PubMedGoogle Scholar
  27. 27.
    Moro, L., Modricky, C., Rovis, L. and de Bernard, B. (1988) Determination of galac-tosyl hydroxylysine in urine as a means for the identification of osteoporotic women. Bone and Mineral 3), 271–276.PubMedGoogle Scholar
  28. 28.
    Fujimoto, D., Moriguchi, T., Ishida, T. and Hayashi, H. (1978) The structure of pyridi-noline, a collagen crosslink. Biochemical and Biophysical Research Communications 84), 52–57.PubMedCrossRefGoogle Scholar
  29. 29.
    Gunja-Smith, Z. and Boucek, R.J. (1981) Collagen crosslink components in human urine. Biochemical Journal 197), 759–762.PubMedGoogle Scholar
  30. 30.
    Robins, S.P. (1982) An enzyme-linked immunoassay for the collagen crosslink, pyridi-noline. Biochemical Journal 207), 617–620.PubMedGoogle Scholar
  31. 31.
    Eyre, D.R., Koob, T.J. and Van Ness, K.P. (1984) Quantitation of hydroxypyridinium crosslinks in collagen by high-performance liquid chromatography. Analytical Biochemistry 137), 380–388.PubMedCrossRefGoogle Scholar
  32. 32.
    Ogawa, T., Ono, T., Tsuda, M. and Kawanashi, Y. (1982) A novel fluor in insoluble collagen: a crosslinking molecule in collagen molecule. Biochemical and Biophysical Research Communications 107), 1252–1257.PubMedCrossRefGoogle Scholar
  33. 33.
    Black, D., Duncan, A. and Robins, S.P. (1988) Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography. Analytical Biochemistry 169), 197–203.PubMedCrossRefGoogle Scholar
  34. 34.
    Pratt, D.A., Daniloff, Y., Duncan, A. and Robins, S.P. (1992) Automated analysis of the pyridinium crosslinks of collagen in tissue and urine using solid-phase extraction and reversed-phase high-performance liquid chromatography. Analytical Biochemistry 207), 168–175.PubMedCrossRefGoogle Scholar
  35. 35.
    Colwell, A., Russell, R. and Eastell, R. (1993) Factors affecting the assay of urinary 3-hydroxy pyridinium crosslinks of collagen as markers of bone resorption. European Journal of Clinical Investigation 23), 341–349.PubMedGoogle Scholar
  36. 36.
    Seibel, M.J., Robins, S.P. and Bilezikian, J.P. (1992) Urinary pyridinium crosslinks of collagen: specific markers of bone resorption in metabolic bone disease. Trends in Endocrinology and Metabolism 3), 263–270.CrossRefPubMedGoogle Scholar
  37. 37.
    Robins, S.P., Duncan, A. and Riggs, B.L. (1990) Direct measurement of free hydroxy-pyridinium crosslinks of collagen in urine as new markers of bone resorption in osteoporosis. Osteoporosis 1990 (eds Christiansen and K. Overgaard), Osteopress ApS, Copenhagen, pp. 465–468.Google Scholar
  38. 38.
    Abbiati, G., Bartucci, F., Longoni, A. et al. (1993) Monitoring of free and total urinary pyridinoline and deoxypyridinoline in healthy volunteers: sample relationships between 24-h and fasting early morning urine concentrations. Bone and Mineral 21), 9–19.PubMedCrossRefGoogle Scholar
  39. 39.
    Seyedin, S., Kung, V., Daniloff, Y. et al (1993) Immunoassay for urinary pyridinoline: the new marker of bone resorption. Journal of Bone and Mineral Research 8), 635–641.PubMedGoogle Scholar
  40. 40.
    Robins, S.P., Woitge, H., Hesley, R. et al. (1994) Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. Journal of Bone and Mineral Research 9), 1643–1649.PubMedCrossRefGoogle Scholar
  41. 41.
    Gomez, B., Ardakani, S., Evans, B. et al. (1996) Monoclonal antibody assay for free urinary pyridinium cross-links. Clinical Chemistry 42), 1168–1175.PubMedGoogle Scholar
  42. 42.
    Risteli, J., Elomaa, I., Niemi, S. et al. (1993) Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clinical Chemistry 39), 635–640.PubMedGoogle Scholar
  43. 43.
    Hanson, D., Weis, M., Bollen, A. et al. (1992) A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. Journal of Bone and Mineral Research 7), 1251–1258.PubMedGoogle Scholar
  44. 44.
    Robins, S.P. (1995) Collagen crosslinks in metabolic bone disease. Acta Orthopaedica Scandinavica Suppl. 266), 171–175.Google Scholar
  45. 45.
    Bonde, M., Qvist, P., Fidelius, C.,et al. (1994) Immunoassay for quantifying type I degradation products in urine evaluated. Clinical Chemistry 40), 2022–2025.PubMedGoogle Scholar
  46. 46.
    Bonde, M., Fledelius, C., Qvist, P. and Christiansen, C., (1996) Coated-tube radioimmunoassay for C-telopeptides of type I collagen to assess bone resorption. Clinical Chemistry 42), 1639–1644.PubMedGoogle Scholar
  47. 47.
    James, LT., Walne, A.J. and Perrett, D. (1996) The measurement of pyridinium crosslinks: a methodological overview. Annals of Clinical Biochemistry 33), 397–420.PubMedGoogle Scholar
  48. 48.
    Eastell, R., Colwell, A., Hampton, L. and Reeve, J. (1997) Biochemical markers of bone resorption compared with estimates of bone resorption from radiotracer kinetic studies in osteoporosis. Journal of Bone and Mineral Research 12), 59–65.PubMedCrossRefGoogle Scholar
  49. 49.
    Tobias, J., Laversuch, C., Wilson, N. and Robins, S.P. (1996) Neridronate preferentially suppresses the urinary excretion of peptide-bound deoxypyridinoline in post-menopausal women. Calcified Tissue International 59), 407–409.PubMedCrossRefGoogle Scholar
  50. 50.
    Garnero, P., Gineyts, E., Arbault, P. et al. (1995) Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. Journal of Bone and Mineral Research 10), 641–649.PubMedGoogle Scholar
  51. 51.
    Randall, A., Kent, G., Garcia Webb, P. et al. (1996) Comparison of biochemical markers of bone turnover in Paget’s disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross-links. Journal of Bone and Mineral Research 11), 1176–1184.PubMedGoogle Scholar
  52. 52.
    Robins, S.P., Duncan, A., Wilson, N.J. and Evans, B.J. (1996) Standardization of the pyridinium crosslinks, pyridinoline and deoxypyridinoline, for use as biochemical markers of collagen degradation. Clinical Chemistry 42), 1621–1626.PubMedGoogle Scholar
  53. 53.
    McLaren, A., Isdale, A., Whiting, P. et al. (1993) Physiological variations in the urinary excretion of pyridinium crosslinks of collagen. British Journal of Rheumatology 32), 307–312.PubMedCrossRefGoogle Scholar
  54. 54.
    Schlemmer, A., Hassager, C., Pedersen, B. and Christiansen, C. (1994) Posture, age, menopause, and osteopenia do not influence the circadian variation in the urinary excretion of pyridinium crosslinks. Journal of Bone and Mineral Research 9), 1883–1888.PubMedGoogle Scholar
  55. 55.
    Gerrits, M., Thijssen, J.H. and van Rijn, H.J.(1995) Determination of pyridinoline and deoxypyridinoline in urine, with special attention to retaining their stability. Clinical Chemistry 41), 571–574.PubMedGoogle Scholar
  56. 56.
    Eriksen, E., Charles, P., Meisen, F. et al. (1993) Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry. Journal of Bone and Mineral Research 8), 127–132.PubMedGoogle Scholar
  57. 57.
    Delmas, P., Schlemmer, A., Gineyts, E. et al. (1991) Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. Journal of Bone and Mineral Research 6), 639–644.PubMedGoogle Scholar
  58. 58.
    Calvo, M., Eyre, D. and Gundberg, C. (1996) Molecular basis and clinical application of biological markers of bone turnover. Endocrinology Reviews 17), 333–368.CrossRefGoogle Scholar
  59. 59.
    van Daele, P., Seibel, M.J., Burger, H. et al. (1996) Case-control analysis of bone resorption markers, disability and hip fracture risk: the Rotterdam study. British Medical Journal 312), 482–483.PubMedGoogle Scholar
  60. 60.
    Garnero, P., Hausherr, E., Chapuy, M. et al. (1996) Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study. Journal of Bone and Mineral Research 11), 1531–1538.PubMedGoogle Scholar
  61. 61.
    Apone, S., Lee, M. and Eyre, D.R. (1996) Osteoclasts generate NTX, the collagen telopeptide marker of bone resorption, but not free pyridinolines. Journal of Bone and Mineral Research 11(Suppl. 1), SI 89.Google Scholar
  62. 62.
    Foged, N., Delaisse, J-M., Hou, P. et al. (1996) Quantification of the collagenolytic activity of isolated osteoclasts by enzyme-linked immunosorbent assay. Journal of Bone and Mineral Research 11), 226–237.PubMedGoogle Scholar
  63. 63.
    Scheven, B. Milne, J. and Robins, S.P. (1997) A novel culture system to generate osteoclasts and bone resorption using porcine bone marrow cells: role of M-CSF. Biochemical and Biophysical Research Communications, 231), 231–235.PubMedCrossRefGoogle Scholar

Copyright information

© Chapman and Hall Ltd 1998

Authors and Affiliations

  • Simon P. Robins

There are no affiliations available

Personalised recommendations